Skip to main content

Qiagen Reports 9-Percent Increase in Q4 Sales; Consumables Segment Jumps 11 Percent

NEW YORK, Feb. 14 (GenomeWeb News) - Qiagen yesterday reported a 9-percent increase in sales and a 6-percent rise in net profit for the fourth quarter.

 

Revenues for the three months ended Dec. 31, 2005, increased to $104.3 million from $95.5 million in the year-ago period.

 

Qiagen's net income for the fourth quarter rose to $16.9 million from $15.8 million in Q4 2004.

 

The company's consumables business, which contributed about 88 percent to net sales, grew approximately 11 percent in the fourth quarter compared with the same period one year ago.

 

R&D expenses for the fourth quarter rose to $10.7 million from $9.5 million in Q4 2004, Qiagen said.

 

As of Dec. 31, Qiagen had approximately $191.7 million in cash and cash equivalents on hand.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.